BioSpace News Archive

Liminal BioSciences Inc., a clinical-stage biopharmaceutical company focused on developing novel therapeutics to treat unmet needs in patients with liver, respiratory and kidney disease, provided a corporate update and outlined its key corporate and R&D priorities for 2020.

DiNAQOR AG announced a research collaboration and exclusive license agreement with UCL to develop novel gene therapies for the treatment of monogenic cardiomyopathies, diseases of the heart muscle that can lead to heart failure in children and adults.

Achieve Life Sciences, Inc., University of Bristol, and Oracle Corporation announced the outcome of a study using Oracle’s high-performance cloud infrastructure to potentially improve the speed of drug discovery and development of new treatments.

ARAZLO Lotion Demonstrated Statistically Significant Superiority Over Placebo with Favorable Efficacy, Safety and Tolerability Profile

Company to Commence Commercial Launch Shortly, Under Brand Name NUMBRINO®

Eagle Pharmaceuticals, Inc. announced that Eagle and the University of Pennsylvania have agreed on terms of a new exclusive worldwide license agreement for the development of dantrolene sodium for the potential treatment of people living with Alzheimer’s disease, including an agreement to fund additional research and provisions regarding commercialization of products developed under the license.

Specialized Expertise, Coordinated Capabilities and Targeted Investments Designed to Accelerate Development and Reduce Risk for Sponsors

Axogen, Inc., a global leader in developing and marketing innovative surgical solutions for peripheral nerve injuries, announced preliminary unaudited fourth quarter and full-year 2019 revenue.

Retrophin, Inc. announced that, based on preliminary and unaudited financial data, the Company expects net product sales for the fourth quarter of 2019 to be approximately $47 million.

CareDx, Inc. reported preliminary financial results for the fourth quarter and full year ended December 31, 2019.